Clinical Implications of Dihydropyrimidine Dehydrogenase Deficiency in GI and Hepatopancreaticobiliary Cancers Treated With Fluoropyrimidines: A Prospective Observational Study
Individuals with DPYD mutations experience increased toxicity and dose adjustments; however, treatment efficacy was not affected. This indicates that a coordinated effort that incorporates routine DPYD testing can mitigate treatment toxicities and individualized fluoropyrimidine dosing for patients with GI and HPB cancers.
Authors
- Anurag Mehta (ORCID: https://orcid.org/0000-0001-6517-3664)
- Dharmishtha Basu (ORCID: https://orcid.org/0000-0003-1602-0543)
- Akanksha Jaju
- Varun Goel (ORCID: https://orcid.org/0000-0003-3590-3261)
- Vineet Talwar (ORCID: https://orcid.org/0000-0001-9149-6969)
- Arpit Jain (ORCID: https://orcid.org/0000-0002-3916-4411)
- Nivedita Patnaik (ORCID: https://orcid.org/0000-0002-9770-1246)
Institutions
- Vardhman Mahavir Medical College & Safdarjung Hospital (IN)
- Max Super Speciality Hospital (IN)
- Rajiv Gandhi Cancer Institute and Research Centre (IN)
- BLK Super Speciality Hospital (IN)
Publication Details
- Journal
- JCO Global Oncology
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1200/go-25-00442
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00